2 CHLORODEOXYADENOSINE FOR CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS

2 氯脱氧腺苷治疗慢性进行性多发性硬化症

• 批准号: 6118104
• 负责人: Ernest Beutler
• 金额: $ 2.74万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6118104
• 关键词: chlorodeoxyadenosine; chronic disease /disorder; clinical research; clinical trials; drug administration rate /duration; drug administration routes; drug screening /evaluation; human subject; human therapy evaluation; injection /infusion; longitudinal human study; magnetic resonance imaging; multiple sclerosis; nervous system disorder chemotherapy; placebos

This study aims to expand the work done on the previous (subproject 220) protocol by administering 2-CdA to patients with documented chronic progressive multiple sclerosis with a subcutaneous injection given for five days each month for six months in a double-blind, placebo-controlled, crossover design. MRI will be followed at baseline, and at 6, 12, 18 and 25 months after initiation of therapy. Standardized neurological rating assessments will be applied.

本研究旨在扩展先前（子项目220）方案的工作，在双盲、安慰剂对照、交叉设计中，对有记录的慢性进行性多发性硬化症患者给予2-CdA，每月皮下注射5天，持续6个月。MRI将在基线、治疗开始后6、12、18和25个月进行随访。将采用标准化的神经系统评分评估。